Oscient Factive Rash Risk In Acute Sinusitis To Be Discussed By Cmte.

FDA’s Anti-Infective Drugs Advisory Committee will consider if five-day treatment will lessen risk of gemifloxacin-associated rash at its Sept. 12 meeting.